What is molecular profile gene-sequenced-based therapy?

Written by: Professor Hany Eldeeb
Published:
Edited by: Conor Lynch

In one of our latest articles below, highly regarded and qualified consultant medical and clinical oncologist, Professor Hany Eldeeb, provides a detailed account of molecular profile gene-sequenced-based therapy.

What is molecular profile gene-sequenced-based therapy?

It is a method that detects the presence of specific biomarkers – genes, proteins, or other molecules – in either tumour tissue or blood samples.
This approach of treatment does not replace the standard of care. Sometimes, we might detect mutations, but we still do not have a target drug to use as treatment.

 

Who is it suitable for?

It could be used at an early stage of cancer diagnosis to help with the outlining of the patient’s treatment plan, or it can be used for cancer patients who have not responded well to standard treatment options.

 

What are the associated complications?

Molecular profile gene-sequenced-based therapy also has some associated complications and challenges, such as:

 

  • the cost and availability of molecular profiling tests 
  • adverse side effects

 

These complications highlight the need for further research and development to optimise the use of molecular profile gene-sequenced-based therapy in cancer patients.

 

How effective is it?

In certain circumstances, molecular profiling can identify rare targets that could lead to a tailored treatment to the patient with much better outcomes compared to standard empirical therapy.

 

To consult with Professor Hany Eldeeb today, visit his Top Doctors profile today.

By Professor Hany Eldeeb
Clinical oncology

Professor Hany Eldeeb is a highly accomplished consultant medical and clinical oncologist based in Milton Keynes and Oxford. He has a vast experience in different types of cancer sites that gives him unique experience in both complex cases and in metastatic cancer and more than one primary.

He treats breast cancer, lung cancer, brain cancer, prostate cancer, and cancer metastasis from different tumour sites. He has expertise in using target therapy, immunotherapy, chemotherapy, as well as gene sequenced-based therapy. In addition to that, he is also using state-of-the-art radiotherapy treatment including IMRT, IGRT, stereotactic radiotherapy and SABRT.

He is passionate about treating challenging cases, especially in cases that require outside-the-box thinking. Professor Eldeeb graduated in medicine from Mansoura University in 1989. Following this, he was appointed as an oncology registrar. He completed his MSc in 1995 and then undertook the roles of assistant lecturer and specialist in oncology.

He then pursued training at St Bart’s hospital in London and completed his MD in 2001. He has studied tirelessly throughout his career and was awarded a Professorship in Clinical Oncology in 2012. He has been working over the last 20 years as a consultant between Northampton, Milton Keynes and Oxford University Hospitals.

Alongside his focus on breast and lung cancer, Professor Eldeeb takes a keen interest in prostate cancer and brain tumours. He has undertaken many managerial roles in theses trusts and currently is the oncology lead at Milton Keynes and was a key member in establishing the newly opened cancer centre there. He currently leads a developing radiotherapy centre at Milton Keynes that is planned to open in 2024. 

Furthermore, he enjoys sharing his medical knowledge with others, working as an educational supervisor for postgraduate trainees in oncology at Milton Keynes and Oxford University Hospital as well as undergraduate student teaching for Buckingham medical school. Professor Eldeeb is a member of multiple organisations, including the prestigious Royal College of Radiologists, The European Society of Breast Cancer Specialists, The European Society for Medical Oncology, and European Society for Radiotherapy and Oncology .

View Profile

Overall assessment of their patients


  • Related procedures
  • Prostate cancer
    Breast cancer
    Bone cancer
    Nervous system malformations
    Brain tumour
    Bone marrow cancers
    Testicular cancer
    Thyroid cancer
    Adrenal glands cancer
    Neuro-oncology
    This website uses our own and third-party Cookies to compile information with the aim of improving our services, to show you advertising related to your preferences as well analysing your browsing habits. You can change your settings HERE.